Equities Analysts Offer Predictions for XFOR FY2024 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at HC Wainwright lowered their FY2024 EPS estimates for X4 Pharmaceuticals in a research report issued on Thursday, November 14th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.66) per share for the year, down from their previous estimate of ($0.60). HC Wainwright currently has a “Buy” rating and a $1.50 price objective on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.04 EPS.

Separately, Stifel Nicolaus dropped their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $0.37 on Monday. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm has a market cap of $62.76 million, a PE ratio of -4.11 and a beta of 0.39. X4 Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.60. The stock has a fifty day moving average price of $0.57 and a 200-day moving average price of $0.74.

Insider Activity at X4 Pharmaceuticals

In other news, COO Mary Dibiase sold 67,695 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the sale, the chief operating officer now directly owns 452,060 shares of the company’s stock, valued at $257,674.20. This represents a 13.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Paula Ragan sold 239,436 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the transaction, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at $581,742.15. The trade was a 18.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 580,800 shares of company stock worth $321,447 over the last three months. Company insiders own 1.62% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp boosted its holdings in X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in shares of X4 Pharmaceuticals by 4.6% in the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock worth $1,477,000 after acquiring an additional 111,032 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of X4 Pharmaceuticals by 15.1% during the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock worth $418,000 after purchasing an additional 81,968 shares in the last quarter. GSA Capital Partners LLP acquired a new position in X4 Pharmaceuticals in the 3rd quarter valued at $340,000. Finally, K2 Principal Fund L.P. purchased a new position in X4 Pharmaceuticals in the 2nd quarter valued at $284,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.